START with a live attenuated vaccine1,2

FluMist Quadrivalent is engineered to help prevent influenza, not cause it.1,3,4
To learn more, click to open each section below.

Live Attenuated Vaccine

The live attenuated influenza virus strains in FluMist Quadrivalent are:

Attenuated

The disease-causing properties are modified and cannot cause influenza 1

Cold-Adapted

The virus strains replicate efficiently in the cooler areas of the nasopharynx at 25°C to initiate an immune response in the nose1

Temperature-Sensitive

The virus strains do not replicate in the lungs where infection occurs1

The virus strains in FluMist Quadrivalent continuously replicate in the lining of the nasopharynx for up to 28 days to induce immunity3,5

FluMist Quadrivalent is a live attenuated vaccine, like the
vaccines for MMR, varicella, and rotavirus1

Replication = shedding

Shedding Decreases as age increases1

Replication = Shedding

Viral replication is necessary for the vaccine to work1,3-5

  • Viral shedding occurs as FluMist Quadrivalent (LAIV) strains replicate in the nasopharynx of the recipient after vaccination1,3-5
  • This is to be expected as part of a normal immune response
  • Vaccine virus shedding is measured by obtaining a nasal swab from the anterior nasal mucosa1

Shedding LAIV illness in others

Although shedding occurs in both children and adults to elicit an immune response, it does not result in illness in others1,4

The shed virus must first be transmitted, then revert to wild type in order for illness
in others to occur6-8

Shedding LAIV does not equal illness in others.

With at least 5 attenuating points in each strain, the odds of reversion to wild-type influenza are 1 in 100,000,000,000,000,000,000 (1 in 100 quintillion) replication cycles (1x1020 replication cycles), which is more than a millennium in time6-8

No evidence of reversion has been observed in the recovered vaccine strains that have been tested1

Important Safety Information

FluMist Quadrivalent is a vaccine indicated for active immunization of persons 2‑49 years of age for the prevention of influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. FluMist Quadrivalent is for intranasal administration only.

FluMist Quadrivalent is contraindicated in persons who have had a severe allergic reaction to any vaccine component, including egg protein, or after a previous dose of any influenza vaccine, and in children and adolescents receiving concomitant aspirin or aspirin-containing therapy.

In clinical trials, the risks of hospitalization and wheezing were increased in children <24 months of age who received trivalent FluMist® (Influenza Vaccine Live, Intranasal). Children <5 years of age with recurrent wheezing and persons of any age with asthma may be at increased risk of wheezing following FluMist Quadrivalent administration. FluMist Quadrivalent has not been studied in persons with severe asthma or active wheezing.

If Guillain‑Barré syndrome has occurred within 6 weeks of any prior influenza vaccination, the decision to give FluMist Quadrivalent should be based on careful consideration of the potential benefits and risks. FluMist Quadrivalent has not been studied in immunocompromised persons. The safety of FluMist Quadrivalent in individuals with underlying medical conditions predisposing them to wild-type influenza infection complications has not been established. FluMist Quadrivalent may not protect all individuals receiving the vaccine.

The most common solicited adverse reactions (occurring ≥10% in vaccine recipients and at least 5% greater than in placebo) reported after FluMist were runny nose or nasal congestion in all persons 2-49 years, fever >100°F in children 2‑6 years, and sore throat in adults 18‑49 years. Among children 2‑17 years who received FluMist Quadrivalent, 32% reported runny nose or nasal congestion and 7% reported fever >100°F. Among adults 18‑49 years who received FluMist Quadrivalent, 44% reported runny nose or nasal congestion and 19% reported sore throat.

Please see accompanying complete Prescribing Information for FluMist Quadrivalent, including Patient Information.

open

Select safety information

The most common side effects are runny or stuffy nose, sore throat, and fever over 100ºF. Click the OPEN tab for Important Safety and Eligibility Information

Important Safety and Eligibility Information

FluMist® Quadrivalent (Influenza Vaccine Live, Intranasal) is a vaccine indicated for active immunization of persons 2‑49 years of age for the prevention of influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. FluMist Quadrivalent is for intranasal administration only.

FluMist Quadrivalent is contraindicated in persons who have had a severe allergic reaction to any vaccine component, including egg protein, or after a previous dose of any influenza vaccine, and in children and adolescents receiving concomitant aspirin or aspirin-containing therapy.

In clinical trials, the risks of hospitalization and wheezing were increased in children <24 months of age who received trivalent FluMist® (Influenza Vaccine Live, Intranasal). Children <5 years of age with recurrent wheezing and persons of any age with asthma may be at increased risk of wheezing following FluMist Quadrivalent administration. FluMist Quadrivalent has not been studied in persons with severe asthma or active wheezing.

If Guillain‑Barré syndrome has occurred within 6 weeks of any prior influenza vaccination, the decision to give FluMist Quadrivalent should be based on careful consideration of the potential benefits and risks. FluMist Quadrivalent has not been studied in immunocompromised persons. The safety of FluMist Quadrivalent in individuals with underlying medical conditions predisposing them to wild-type influenza infection complications has not been established. FluMist Quadrivalent may not protect all individuals receiving the vaccine.

The most common solicited adverse reactions (occurring ≥10% in vaccine recipients and at least 5% greater than in placebo) reported after FluMist were runny nose or nasal congestion in all persons 2‑49 years, fever >100°F in children 2‑6 years, and sore throat in adults 18‑49 years. Among children 2‑17 years who received FluMist Quadrivalent, 32% reported runny nose or nasal congestion and 7% reported fever >100°F. Among adults 18‑49 years who received FluMist Quadrivalent, 44% reported runny nose or nasal congestion and 19% reported sore throat.

Please see complete Prescribing Information for FluMist Quadrivalent, including Patient Information.